|本期目录/Table of Contents|

[1]谢榆,郭峰.非布司他研究现状及临床应用进展[J].生物加工过程,2019,17(02):184-188.[doi:10.3969/j.issn.1672-3678.2019.02.011]
 XIE Yu,GUO Feng.Progress in the clinical application of febuxostat[J].Chinese Journal of Bioprocess Engineering,2019,17(02):184-188.[doi:10.3969/j.issn.1672-3678.2019.02.011]
点击复制

非布司他研究现状及临床应用进展()
分享到:

《生物加工过程》[ISSN:1672-3678/CN:32-1706/Q]

卷:
17
期数:
2019年02期
页码:
184-188
栏目:
出版日期:
2019-03-30

文章信息/Info

Title:
Progress in the clinical application of febuxostat
文章编号:
1672-3678(2019)02-0184-05
作者:
谢榆郭峰
江苏省中医院 风湿科,江苏 南京 210029
Author(s):
XIE YuGUO Feng
Rheumatology Department,Jiangsu Province Hospital of TCM,Nanjing 210029,China
关键词:
痛风 非布司他 高尿酸血症 黄嘌呤氧化酶抑制剂 生物医药
分类号:
R589
DOI:
10.3969/j.issn.1672-3678.2019.02.011
文献标志码:
A
摘要:
非布司他是一种选择性黄嘌呤氧化酶抑制剂,主要应用于痛风及高尿酸血症的治疗。由于其降尿酸效果好,不良反应发生率低,目前在临床方面的应用越来越广泛。笔者就非布司他的药理作用、药代动力学、制备工艺及临床应用进展做了综述,以期为临床医学和药学工作者提供参考。

参考文献/References:

[1] 李丹,张剑勇.痛风现代流行病学及其降尿酸药物研究进展[J].风湿病与关节炎,2016(4):73-76.
[2] 中华医学会风湿病分会.2016中国痛风诊疗指南[J].中华内科杂志,2016,55(11):892-897.
[3] OKAMOTO K,EGER B T,NISHINO T,et al.An extremely potent inhibitor of xanthine oxidoreductase.crystal structure of the enzyme-inhibitor complex and mechanism[J].J Biol Chem,2003,278(3):1848-1855.
[4] 汤艳华,江敏,刘玲,等.非布司他治疗痛风伴高尿酸血症患者的临床研究[J].中国当代医药,2016,23(21):40-42.
[5] 陈松,黄健,杨静,等.非布司他治疗慢性肾脏病伴高尿酸血症的临床研究[J].实用医学杂志,2016,32(3):472-474.
[6] 施政,刘健,申屠建中,等.非布司他片在中国健康人体的生物等效性[J].中国临床药理学杂志,2013,29(4):276-279.
[7] KAMEL B,GRAHAM G G,WILLIAMS K M,et al.Clinical pharmacokinetics and pharmacodynamics of febuxostat[J].Clin Pharmacokinet,2017,56(5):459-475.
[8] 赵娜.健康受试者口服非布司他片的药代动力学研究[M].沈阳:沈阳药科大学出版社,2015.
[9] 李宏.非布司他原料药合成工艺及质量研究[D].杭州:浙江大学,2018.
[10] 陆皞然,程玉红,张彦巧,等.抗痛风药非布司他的合成方法研究进展[J].广东化工,2017,44:64-65.
[11] 江苏同禾药业有限公司.一种2-(3-氰基-4-异丁基氧基苯基)-4-甲基噻唑-5-甲酸乙酯的制备方法:102070559A[P].2011-05-25.
[12] 药源药物化学(上海)有限公司.一种非布司他的制备方法:102120733A[P].2011-07-13.
[13] TEIJIN L T D.2-arylthiazole derivative and pharmaceutical composition containing the same:JP0513379[P].1992-11-19.
[14] 重庆莱美药业股份有限公司.一种制备非布司他中间体的方法:102234253A[P].2011-11-09.
[15] BECKER M A,SCHUMACHER H R,ESPINOZA L R,et al.The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemiaof gout:the confirms trial[J].Arthritis Res Ther,2010,12:63.
[16] BECKER M A,SCHUMACHER H R,WORTMANN R L,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout[J].New Engl J Med,2005,353(23):2450-2461.
[17] SCHUMACHER J R H R,BECKER M A,WORTMANN R L,et al.Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout:a 28-week,phase Ⅲ,randomized,double-blind,parallel-group trial[J].Arthritis Care Res,2008,59:1540-1548.
[18] KAMATANI N,FUJIMORI S,HADA T,et al.An allopurinol- controlled,randomized,double-dummy,double-blind,parallel between-group,comparative study of febuxostat(TMX-67),a non- purine-selective inhibitor of xanthine oxidase,in patients with hyperuricemia including those with gout in Japan:phase 3 clinical study[J].J Clin Rheumatol,2011,17(Sup 2):13-18.
[19] NAOYUKI K,SHIN F,TOSHIKAZU H,et al.An allopurinol controlled,multicenter,randomized,open label,parallel between group,comparative study of febuxostat(TMX-67),a non-purine-selective inhibitor of xanthine oxidase,in patients with hyperuricemia including those with gout in Japan:phase 2 exploratory clinical study[J].J Clin Rheumatol,2011,17(Sup 2):44-49.
[20] 杨婷,路敏,周颖,等.非布司他和别嘌醇治疗痛风有效性和安全性的Meta分析[J].中国临床药理学杂志,2015(2):122-126.
[21] 马骁,张志欣,蔡剑平,等.中国高尿酸血症患者HLA-B5801基因的人群分布[J].国际检验医学杂志,2016,37(24):3395-3399.
[22] BRUCE S P.Febuxostat:a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout[J].Ann Pharmacother,2006,40(12):2187-2194.
[23] 韩莹,朱翊,傅得兴.非布司他治疗高尿酸血症伴痛风的药理与临床评价[J].中国新药与临床杂志,2010(8):635-638.
[24] EDWARDS N L.Febuxostar:a new treatment for hyperuricaemia in gout[J].Rheumatology,2009,48(Sup 2):15-19.
[25] FDA.Administration drug safety communication:FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicia febuxostat(Uloric)[M/OL].[2018-06-06].http://www.fda.gov/Drugs/Drug safety/ucm58470.

备注/Memo

备注/Memo:
收稿日期:2018-06-11修回日期:2018-07-12
作者简介:谢榆(1987—),男,江苏南京人,主治医师,研究方向:风湿病的诊治; 郭峰(联系人),副主任医师,E-mail:178837922@qq.com
引文格式:谢榆,郭峰.非布司他研究现状及临床应用进展[J].生物加工过程,2019,17(2):184-188.
XIE Yu,GUO Feng.Progress in the clinical application of febuxostat[J].Chin J Bioprocess Eng,2019,17(2):184-188..
更新日期/Last Update: 2019-03-30